Last reviewed: June 16, 2026
Last updated: June 16, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Reproductive health depends on complex interactions between body weight, insulin sensitivity, and hormone regulation—systems directly influenced by GLP-1 receptor agonist therapy. Semaglutide and similar medications work by improving blood sugar control and promoting gradual weight loss, changes that research suggests may positively affect fertility outcomes in both women and men. This article explores the evidence connecting GLP-1 therapy to reproductive health improvements.
How GLP-1 Medications Influence Reproductive Hormones
Excess body weight and insulin resistance disrupt the delicate balance of reproductive hormones, including luteinizing hormone (LH), follicle-stimulating hormone (FSH), and testosterone. When cells become resistant to insulin, the ovaries and testes often respond by producing excess androgens, creating an imbalance that impairs ovulation and sperm quality. GLP-1 receptor agonists improve insulin sensitivity at the cellular level, allowing the endocrine system to restore more typical hormone ratios without requiring pharmaceutical hormone manipulation.
Research demonstrates that even modest weight loss—as little as 5 to 10 percent of body weight—can measurably improve reproductive hormone profiles in individuals with obesity. Semaglutide achieves this through dual mechanisms: reducing appetite signals in the brain and slowing gastric emptying, both of which facilitate sustainable calorie reduction. Studies on semaglutide users show improvements in fasting insulin levels within 8 to 12 weeks, suggesting that hormonal restoration may begin before significant weight loss occurs.
Semaglutide, Polycystic Ovary Syndrome, and Ovulation
Polycystic ovary syndrome (PCOS) affects approximately 1 in 10 women of reproductive age and is the leading cause of anovulation—failure to release an egg during the menstrual cycle. PCOS is fundamentally an insulin resistance disorder; women with PCOS have significantly elevated fasting insulin levels compared to weight-matched controls without the condition. Compounded semaglutide addresses the root metabolic dysfunction in PCOS by improving insulin action, which in turn reduces ovarian androgen production and can restore regular ovulatory cycles.
Clinical observations and early research suggest that semaglutide users with PCOS report more regular menstrual cycles and improved ovulation markers within 3 to 6 months of therapy initiation. The mechanism differs from traditional PCOS treatments like metformin or spironolactone because semaglutide reduces insulin demand rather than merely lowering circulating glucose. Weight loss accompanying semaglutide therapy further decreases systemic inflammation and adipokine dysregulation, both hallmarks of PCOS-related infertility.
Body Weight, Metabolic Health, and Male Reproductive Function
Obesity impairs male fertility through multiple pathways: elevated scrotal temperature from excess abdominal fat, oxidative stress in testicular tissue, hormonal imbalances (reduced testosterone and increased estrogen), and reduced sperm motility and morphology. Men with a body mass index (BMI) above 30 show significantly lower sperm concentration and quality compared to normal-weight men, effects that often reverse with weight loss. Semaglutide-induced weight loss may restore testicular function by normalizing local temperature, improving antioxidant defense, and restoring the testosterone-to-estrogen ratio.
Research on GLP-1 agonists in male populations remains limited, but observational data from semaglutide users indicate improvements in erectile function and sexual satisfaction alongside weight loss. These improvements likely reflect enhanced vascular endothelial function from improved insulin sensitivity and reduced inflammation, factors that support erectile physiology. The metabolic gains from semaglutide therapy may therefore benefit male reproductive health indirectly through improved cardiovascular and endothelial health.
Compounded Semaglutide vs. Brand Medications for Fertility Goals
PlexusDx offers compounded semaglutide injection starting at $149 per month through licensed 503A compounding pharmacies, providing access to the same active pharmaceutical ingredient as brand formulations without insurance requirements or membership fees. Compounded semaglutide delivers identical metabolic and reproductive hormone benefits as brand Ozempic or Wegovy because the active ingredient and mechanism of action are identical; the distinction lies in cost, accessibility, and supply reliability. Individuals pursuing fertility improvement through weight loss and metabolic optimization can achieve these goals with PlexusDx compounded semaglutide at a fraction of brand-name pricing.
PlexusDx also offers the Precision Peptide Genetic Test ($99 add-on after the first month) to identify individual variations in GLP-1R and GIPR gene variants that may predict response patterns. Understanding genetic predispositions to GLP-1 therapy efficacy allows personalized dose titration and helps determine whether semaglutide, tirzepatide, or the GLP-Squared dual compound offers the best metabolic and reproductive outcomes for each patient. This precision approach to fertility-focused weight loss therapy distinguishes PlexusDx from standard pharmacy or direct-to-consumer options.
Timeline: When to Expect Fertility Improvements on GLP-1 Therapy
Hormonal improvements often precede noticeable weight loss: fasting insulin levels typically decrease within 4 to 8 weeks, while menstrual cycle regularity in PCOS may improve within 8 to 12 weeks, and clinically meaningful weight loss (5 to 10 percent) usually occurs by 3 to 4 months. This timeline is important for individuals planning conception because reproductive hormone restoration may enhance fertility before substantial body composition change is visible. Tracking baseline reproductive markers (fasting insulin, testosterone, FSH/LH ratios, or ovulation patterns) before starting semaglutide allows objective assessment of treatment efficacy.
Conception attempts should ideally begin after at least 3 months of semaglutide therapy and documented hormonal improvement, as this timing maximizes the likelihood of restored ovulation in women and improved sperm parameters in men. PlexusDx patients can coordinate with their prescribing clinician to monitor these improvements through routine blood work and symptom tracking, ensuring that fertility goals align with metabolic milestones throughout therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Can semaglutide directly improve fertility, or does it only work through weight loss?
Semaglutide improves fertility through multiple mechanisms beyond weight loss alone: it directly enhances insulin sensitivity, reduces systemic inflammation, and restores reproductive hormone balance. These metabolic improvements may begin within weeks, even before significant weight reduction occurs. Weight loss amplifies these benefits by reducing adipose tissue inflammation and normalizing hormone signaling.
Is compounded semaglutide from PlexusDx as effective as brand Wegovy for fertility outcomes?
Yes. PlexusDx compounded semaglutide contains the identical active ingredient and achieves the same insulin sensitivity and weight loss outcomes as brand Wegovy. Both deliver equivalent reproductive hormone improvements. PlexusDx pricing starts at $149 per month, making the therapy accessible without insurance or membership fees.
How does the Precision Peptide Genetic Test help with fertility planning?
The Precision Peptide Genetic Test analyzes variants in GLP1R and GIPR genes that predict individual response to GLP-1 therapy. Understanding your genetic predispositions helps PlexusDx clinicians optimize your dose and medication selection (semaglutide, tirzepatide, or GLP-Squared) for maximum metabolic and fertility benefit. The test is available for $99 after your first month of treatment.
Are there any safety concerns about semaglutide for individuals trying to conceive?
Semaglutide has no known adverse effects on fetal development, but it is typically discontinued during pregnancy as a precaution due to limited human pregnancy data. The weight loss and metabolic improvements achieved before conception persist, supporting healthier pregnancy outcomes. Discuss pregnancy planning with your PlexusDx clinician to time medication adjustments appropriately.
How long should I use semaglutide before attempting to conceive?
Most reproductive benefits emerge within 3 to 6 months: hormone levels normalize, menstrual cycles may regularize (in PCOS), and meaningful weight loss begins. Waiting at least 3 months allows objective assessment of fertility marker improvement and ensures maximum benefit before conception attempts. PlexusDx clinicians can monitor your progress through routine bloodwork and symptom tracking.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Achieving Sustainable Weight Loss: How Long Does It Take to See Results on Wegovy?
What to Do If Ozempic Leaked Out of Injection Site: Essential Tips and Techniques